NASDAQ:ISPC

iSpecimen Stock Forecast, Price & News

$5.70

-0.45 (-7.32 %)

(As of 08/4/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.69

▼

$6.22

50-Day Range N/A

52-Week Range

$5.10

▼

$10.00

Volume115,046 shs

Average Volume685,177 shs

Market Capitalization$37.00 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive ISPC News and Ratings via Email

Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter.

About iSpecimen

iSpecimen, Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

iSpecimen (ISPC) to Release Quarterly Earnings on Tuesday
August 3, 2021 | americanbankingnews.com

iSpecimen Inc.
July 28, 2021 | barrons.com

iSpecimen Announces Closing of Over-Allotment Option in Connection with its Initial Public Offering
July 28, 2021 | finance.yahoo.com

iSpecimen to Report Second Quarter 2021 Results on August 10, 2021
July 28, 2021 | finance.yahoo.com

PPD (NASDAQ:PPD) & iSpecimen (NASDAQ:ISPC) Financial Comparison
July 22, 2021 | americanbankingnews.com

iSpecimen Inc.'s Quiet Period Set To Expire on July 27th (NASDAQ:ISPC)
July 20, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ISPC
Previous Symbol
CUSIPN/A
CIKN/A
Webispecimen.com
Phone781 301 6700
Employees46
Year FoundedN/A

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares6,492,000
Market Cap$37.00 million
Next Earnings Date8/10/2021 (Confirmed)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1283rd out of 1,311 stocks

Commercial Physical Research Industry

22nd out of 23 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for iSpecimen.

0.0 Community Rank

Outperform Votes
iSpecimen has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
iSpecimen has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about iSpecimen and other stocks. Vote “Outperform” if you believe ISPC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ISPC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
iSpecimen does not currently pay a dividend.
Dividend Growth
iSpecimen does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, iSpecimen insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

iSpecimen (NASDAQ:ISPC) Frequently Asked Questions

What stocks does MarketBeat like better than iSpecimen?

Wall Street analysts have given iSpecimen a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iSpecimen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is iSpecimen's next earnings date?

iSpecimen is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for iSpecimen.

How can I listen to iSpecimen's earnings call?

iSpecimen will be holding an earnings conference call on Tuesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13721607".

Who are iSpecimen's key executives?

iSpecimen's management team includes the following people:

Dr. Christopher J. Ianelli Ph.D., M.D., Founder, Pres, CEO & Director
Ms. Tracy Wilson Curley, Chief Financial Officer (Age 59, Pay $253.44k)
Ms. Jill Mullan, COO, Treasurer, Sec. & Director (Age 56, Pay $230k)
Mr. Benjamin Bielak, Chief Information Officer (Age 52, Pay $220k)
Mr. Eric Langlois, Sr. VP of Sales & Bus. Devel.
Ms. Carly Lejnieks, Sr. Director of Marketing
Mr. David Wages M.D., Ph.D., Chief Medical Officer

Who are some of iSpecimen's key competitors?

Some companies that are related to iSpecimen include Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI), AIkido Pharma (AIKI), AIkido Pharma (AIKI), Bioqual (BIOQ), Eloxx Pharmaceuticals (ELOX), ProMIS Neurosciences (ARFXF), Vitality Biopharma (VBIO), U.S. Stem Cell (USRM), Protalex (PRTX), DNAPrint Genomics (DNAG), Affinity Energy and Health (ALGXY), Deltagen (DGEN) and Redpoint Bio (RPBC).
View all of ISPC's competitors.

When did iSpecimen IPO?

(ISPC) raised $20 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 2,200,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is iSpecimen's stock symbol?

iSpecimen trades on the NASDAQ under the ticker symbol "ISPC."

When did the company's quiet period expire?

iSpecimen's quiet period expired on Tuesday, July 27th. iSpecimen had issued 2,250,000 shares in its initial public offering on June 17th. The total size of the offering was $18,000,000 based on an initial share price of $8.00. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of iSpecimen?

Shares of ISPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iSpecimen's stock price today?

One share of ISPC stock can currently be purchased for approximately $5.70.

How much money does iSpecimen make?

iSpecimen has a market capitalization of $37.00 million.

How many employees does iSpecimen have?

iSpecimen employs 46 workers across the globe.

What is iSpecimen's official website?

The official website for iSpecimen is ispecimen.com.

How can I contact iSpecimen?

The company can be reached via phone at 781 301 6700 or via email at [email protected]

This page was last updated on 8/5/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here